Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Shugan Ningxin Granules for mild to moderate generalized anxiety disorder
CTR20263939Phase 2Active
- Sponsor
- Institute of Chinese Materia Medica
- Start
- Oct 2026
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of Shugan Ningxin Granules in generalized anxiety disorder (GAD), sponsored by Institute of Chinese Materia Medica. Started Oct 2026; status: active.
02
Drugs
Shugan Ningxin Granules
03
Conditions
generalized anxiety disorder (GAD)
Beyond the preview
Go deeper on CTR20263939.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20263939.